You are here

CAR-T

Can CAR-T first movers keep pace in a rapidly evolving market?

Pharmaphorum

Wed, 12/11/24 - 10:59 am

Gilead Sciences

Novartis taps Vyriad’s viral vectors to develop in vivo T cell editing

Fierce Biotech

Wed, 11/20/24 - 08:44 pm

Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval

Fierce Biotech

Thu, 11/14/24 - 11:14 am

relapsed or refractory chronic lymphocytic leukemia

Autolus enters CAR-T race with FDA approval for Aucatzyl

Fierce Pharma

Mon, 11/11/24 - 11:49 am

Autolus Therapeutics

Gilead Sciences

relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit

Fierce Pharma

Thu, 11/7/24 - 11:29 am

Gilead Sciences

Cellectis drops one of its 3 clinical-stage CAR-Ts

Fierce Biotech

Tue, 11/5/24 - 06:19 pm

Pharma 'It was a good lesson': FDA reconsiders CAR-T boxed warning on secondary cancers, Peter Marks says

Fierce Pharma

Fri, 11/1/24 - 11:14 am

After scoring a first for an off-the-shelf CAR-T, can Atara maintain momentum?

Pharma Voice

Mon, 09/30/24 - 09:17 am

Atara Biotherapeutics

Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’

BioPharma Dive

Mon, 09/16/24 - 10:14 pm

Kyverna Therapeutics

Gilead Sciences

Orgenesis touts early clinical promise of CAR-T therapy with decentralized production in mind

Biopharma Reporter

Tue, 09/3/24 - 11:16 am

clinical trials

Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats

Investors Business Daily

Mon, 08/26/24 - 11:11 am

non-Hodgkin lymphoma

Gilead Sciences

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Biopharma Reporter

Thu, 08/22/24 - 11:15 am

multiple sclerosis

clinical trials

Legend Biotech CEO takes ‘close look at business’ amid geopolitical risk, M&A rumor

Fierce Pharma

Fri, 08/9/24 - 11:31 am

Galapagos pauses CAR-T cell therapy trial over Parkinsonism case

Fierce Biotech

Fri, 08/2/24 - 11:36 am

clinical trials

Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder

Pharma Voice

Fri, 07/19/24 - 11:39 am

Kyverna Therapeutics

stiff person syndrome

autoimmune disease

J&J’s CAR-T partner Legend Biotech reportedly receives buyout offer

Fierce Pharma

Mon, 07/15/24 - 11:20 pm

Ones to watch - five upcoming companies on the CAR-T scene

Biopharma Reporter

Mon, 07/8/24 - 11:46 am

Cargo Therapeutics

Capstan Therapeutics

Kyverna Therapeutics

Verismo Therapeutics

J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma

Fierce Pharma

Tue, 07/2/24 - 11:22 am

Multiple Myeloma

clinical trials

Lyell Reports Patient Death in Early-Stage CAR T Trial, Shows Otherwise Strong Response Rate

BioSpace

Wed, 06/26/24 - 10:07 am

Lyell Immunopharma

clinical trials

Secondary Cancer Risk Is Low After CAR-T Cell Treatment: Stanford Study

BioSpace

Thu, 06/13/24 - 11:21 am

Pages